Published in Immunotherapy Weekly, January 12th, 2011
"The current advocated follow-up strategy includes serological follow-up to detect evolution to chronic disease and cardiac screening at baseline to identify and prophylactically treat Q fever patients in case of valvulopathy....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
Source: Immunotherapy Weekly (2011-01-12)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.